Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | GCK | P35557 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812601 | 0.93 | NPC1 (0.49) | IL2NPC1ALDH1A1PKMTSHR | |
| SCHEMBL2815969 | 0.90 | IL2 (0.49) | IL2NPC1ALDH1A1PKMTSHR | |
| SCHEMBL5556084 | 0.88 | STIM1 (0.52) | IL2NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4762631 | 0.87 | IL2 (0.61) | IL2NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5550488 | 0.83 | STIM1 (0.52) | IL2NPC1RAB9APOLBROCK2 | |
| SCHEMBL2812514 | 0.81 | IL2 (0.58) | IL2ABL1 | |
| SCHEMBL5554283 | 0.81 | IL2 (0.44) | IL2ALDH1A1SMN1; SMN2ROCK2 | |
| SCHEMBL8239024 | 0.80 | IL2 (0.54) | IL2NPC1ALDH1A1PKMTSHR | |
| SCHEMBL15853492 | 0.80 | IL2 (0.48) | IL2NPC1ALDH1A1PKMTSHR | |
| SCHEMBL5554329 | 0.80 | IL2 (0.56) | IL2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-03 | — | — | US | claimed |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-09-30 | — | — | US | claimed |
| EP-1984338-A2 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | claimed |
| WO-2007089904-A2 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8710083-B2 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710083-B2 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710083-B2 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-1984338-B1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-09-30 | — | — | US | disclosed |
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | CCR1, CXCR3, NLRP1 | IL2 77/4885NPC1 947/4885ALDH1A1 3023/4885 |
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCR3, NLRP1 | IL2 77/4885NPC1 947/4885ALDH1A1 3023/4885 |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCR3, NLRP1 | IL2 77/4885NPC1 947/4885ALDH1A1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.